These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 26518255)

  • 1. Psychometric validation of the Psoriasis Symptom Diary using Phase III study data from patients with chronic plaque psoriasis.
    Strober B; Zhao Y; Tran MH; Gnanasakthy A; Nyirady J; Papavassilis C; Nelson LM; McLeod LD; Mordin M; Gottlieb AB; Elewski BE; Lebwohl M
    Int J Dermatol; 2016 Mar; 55(3):e147-55. PubMed ID: 26518255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measurement Properties of the Psoriasis Symptom Inventory Electronic Daily Diary in Patients with Moderate to Severe Plaque Psoriasis.
    Viswanathan HN; Mutebi A; Milmont CE; Gordon K; Wilson H; Zhang H; Klekotka PA; Revicki DA; Augustin M; Kricorian G; Nirula A; Strober B
    Value Health; 2017 Sep; 20(8):1174-1179. PubMed ID: 28964451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychometric properties of the Itch Numeric Rating Scale in patients with moderate-to-severe plaque psoriasis.
    Kimball AB; Naegeli AN; Edson-Heredia E; Lin CY; Gaich C; Nikaï E; Wyrwich K; Yosipovitch G
    Br J Dermatol; 2016 Jul; 175(1):157-62. PubMed ID: 26852717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Item-level psychometric properties for a new patient-reported psoriasis symptom diary.
    Strober BE; Nyirady J; Mallya UG; Guettner A; Papavassilis C; Gottlieb AB; Elewski BE; Turner-Bowker DM; Shields AL; Gwaltney CJ; Lebwohl M
    Value Health; 2013; 16(6):1014-22. PubMed ID: 24041351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study.
    Shikiar R; Willian MK; Okun MM; Thompson CS; Revicki DA
    Health Qual Life Outcomes; 2006 Sep; 4():71. PubMed ID: 17005043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM): A Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Reported Data from the BE RADIANT Phase 3b Trial.
    Gottlieb AB; Warren RB; Augustin M; Garcia L; Cioffi C; Peterson L; Pelligra C; Ciaravino V
    Adv Ther; 2021 Oct; 38(10):5253-5269. PubMed ID: 34471992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis.
    Menter A; Kosinski M; Bresnahan BW; Papp KA; Ware JE
    J Drugs Dermatol; 2004; 3(1):27-38. PubMed ID: 14964744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reliability, validity, and the ability to detect change of the Psoriasis Symptom Scale (PSS) in patients with plaque psoriasis.
    Rentz AM; Skalicky AM; Esser D; Zema C; Becker K; Bodhani A; Revicki DA
    J Dermatolog Treat; 2020 Aug; 31(5):460-469. PubMed ID: 32045314
    [No Abstract]   [Full Text] [Related]  

  • 9. Validity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trials.
    Shikiar R; Bresnahan BW; Stone SP; Thompson C; Koo J; Revicki DA
    Health Qual Life Outcomes; 2003 Oct; 1():53. PubMed ID: 14613569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of psychometric properties and development of response criteria for the psoriasis symptoms and signs diary (PSSD): results from a phase 3 clinical trial.
    Armstrong A; Puig L; Langley R; Tsai TF; Song M; Wasfi Y; Jiang J; Li S; Han C
    J Dermatolog Treat; 2019 Feb; 30(1):27-34. PubMed ID: 28797188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study.
    Blauvelt A; Reich K; Tsai TF; Tyring S; Vanaclocha F; Kingo K; Ziv M; Pinter A; Vender R; Hugot S; You R; Milutinovic M; Thaçi D
    J Am Acad Dermatol; 2017 Jan; 76(1):60-69.e9. PubMed ID: 27663079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reliability and validity of the psoriasis symptom inventory in patients with moderate-to-severe psoriasis.
    Revicki DA; Jin Y; Wilson HD; Chau D; Viswanathan HN
    J Dermatolog Treat; 2014 Feb; 25(1):8-14. PubMed ID: 23339373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies.
    Armstrong AW; Reich K; Foley P; Han C; Song M; Shen YK; You Y; Papp KA
    Am J Clin Dermatol; 2019 Feb; 20(1):155-164. PubMed ID: 30417277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measurement properties of a patient-reported outcome measure assessing psoriasis severity: The psoriasis symptoms and signs diary.
    Mathias SD; Feldman SR; Crosby RD; Colwell HH; McQuarrie K; Han C
    J Dermatolog Treat; 2016 Aug; 27(4):322-7. PubMed ID: 26634943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
    Menter A; Gordon K; Carey W; Hamilton T; Glazer S; Caro I; Li N; Gulliver W
    Arch Dermatol; 2005 Jan; 141(1):31-8. PubMed ID: 15655139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.
    Papp KA; Langley RG; Sigurgeirsson B; Abe M; Baker DR; Konno P; Haemmerle S; Thurston HJ; Papavassilis C; Richards HB
    Br J Dermatol; 2013 Feb; 168(2):412-21. PubMed ID: 23106107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE).
    Blauvelt A; Prinz JC; Gottlieb AB; Kingo K; Sofen H; Ruer-Mulard M; Singh V; Pathan R; Papavassilis C; Cooper S;
    Br J Dermatol; 2015 Feb; 172(2):484-93. PubMed ID: 25132411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.
    Feldman SR; Gordon KB; Bala M; Evans R; Li S; Dooley LT; Guzzo C; Patel K; Menter A; Gottlieb AB
    Br J Dermatol; 2005 May; 152(5):954-60. PubMed ID: 15888152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reliability and Validity of the Psoriasis Symptom Inventory in Patients With Psoriatic Arthritis.
    Wilson HD; Mutebi A; Revicki DA; Mease PJ; Genovese MC; Erondu N; Nirula A; Yuan FJ; Viswanathan HN
    Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1750-6. PubMed ID: 26206134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of bodyweight on the efficacy and safety of ixekizumab: results from an integrated database of three randomised, controlled Phase 3 studies of patients with moderate-to-severe plaque psoriasis.
    Reich K; Puig L; Mallbris L; Zhang L; Osuntokun O; Leonardi C
    J Eur Acad Dermatol Venereol; 2017 Jul; 31(7):1196-1207. PubMed ID: 28370467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.